- Matica Biotechnology will provide analytical development, process development, and GMP manufacturing for Calidi Biotherapeutics’ oncolytic virus therapy CLD-401.
Matica Biotechnology, Inc. has announced a strategic partnership with Calidi Biotherapeutics, Inc., a clinical-stage immuno-oncology company developing oncolytic virus-based therapies. The agreement covers analytical development, process development, and GMP manufacturing to support the IND submission for CLD-401, Calidi’s lead candidate from its RedTail platform.
The RedTail platform is designed to deliver genetic medicines through a tumor-tropic oncolytic virus. CLD-401 homes to metastatic sites following systemic administration, replicates selectively in tumour cells, and expresses IL-15 superagonist in the tumour microenvironment to enhance immune responses.
Matica Bio will conduct the work at its dedicated GMP facility in College Station, Texas. The company has established expertise in viral vector manufacturing, including adeno-associated virus (AAV), lentivirus (LVV), and oncolytic viruses, supporting end-to-end development programmes.
“Matica Bio has become a sought-after partner especially in the oncolytic virus space because of our technical expertise, regulatory readiness, and track record of delivering seamless development-to-GMP manufacturing programmes.”
Paul Kim, CEO of Matica Bio
According to Calidi Biotherapeutics’ CEO Eric Poma, Matica Bio’s experience with complex viral vector programmes made it the “clear CDMO of choice” for this project. As the demand for advanced therapies grows, the partnership highlights the expanding role of CDMOs in supporting complex viral vector manufacturing and cancer immunotherapy development.
